COVID-19Global NewsNews

RDIF submits application of Sputnik V vaccine to WHO

The Russian Federation has become one of the first countries to apply to WHO for pre-qualification of its vaccine against the novel coronavirus infection

The Russian Direct Investment Fund (RDIF) Russia’s sovereign wealth fund), has submitted applications to the World Health Organization (WHO) for accelerated registration (Emergency Use Listing, EUL) and pre-qualification of the world’s first registered vaccine against the coronavirus Sputnik V, which is based on a well-studied platform of human adenoviral vectors. The Russian Federation has become one of the first countries to apply to WHO for pre-qualification of its vaccine against the novel coronavirus infection.

THIS CAN BE YOUR ADVERTISEMENT

The Prequalification of Medicines Programme is a United Nations programme managed by WHO. It is the only global medicines quality assurance programme. The WHO pre-qualification of medicines assesses the quality, safety and efficacy of medicines. A medicinal product is included in the list of pre-qualified medicinal products subject to compliance with established requirements and standards of WHO.

In the face of the ongoing pandemic, accelerated vaccine registration under the EUL procedure will make the Russian vaccine available globally in a shorter time frame than usual procedures and will support global efforts to prevent the coronavirus infection. Successful pre-qualification will enable Sputnik V to be included in the list of medicines used by international procurement agencies and countries to guide bulk purchasing of medicines.

Kirill Dmitriev, CEO, Russian Direct Investment Fund, commented, “The Russian Federation was the first in the world to register a vaccine against the coronavirus, Sputnik V, which was created on a safe, effective and well-studied platform of human adenoviral vectors. We have submitted an application for Emergency Use Listing and pre-qualification of the vaccine by the WHO, which will allow Sputnik V to be included in the list of medical products that meet leading quality, safety and efficacy standards. We express our gratitude to WHO for its active cooperation and look forward to the successful completion of the pre-qualification process at all major stages.”

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close